阿托伐他汀对ACS患者血浆炎症因子和颈动脉粥样硬化斑块的影响

目的:探讨阿托伐他汀对急性冠脉综合征(ACS)患者血浆炎症因子和颈动脉粥样硬化斑块的影响。方法:将68例ACS患者随机均分为阿托伐他汀组和对照组。阿托伐他汀组口服阿托伐他汀片20 mg.d-1,连用20周。对照组不口服阿托伐他汀,其他治疗同阿托伐他汀组。结果:2组患者治疗20周后,患者血浆超敏C反应蛋白(hs-CRP)和白细胞介素-18(IL-18)水平均较治疗前明显下降(P<0.05或P<0.01),且阿托伐他汀组下降的幅度更明显(P<0.05)。阿托伐他汀组治疗20周后斑块大小、厚度和颈动脉中层内膜厚度(IMT)均较治疗前明显减小(P<0.05),而斑块数量无明显变化(P>0.05)。对照组治疗前后斑块大小、厚度、数量和IMT均无统计学意义(P>0.05)。结论:阿托伐他汀对ACS患者具有抗炎作用,能改善血管内斑块的炎症反应,具有阻断和逆转冠状动脉粥样斑块的作用。

Effect of Atorvastatin on Inflammatory Factors and Carotid Atherosclerosis Plaques in Patients with Acute Coronary Syndrome

OBJECTIVE： To investigate the effects of atorvastatin on inflammatory factors and carotid atherosclerotic plaques in patients with acute coronary syndrome （ACS）. METHODS： 68 ACS patients were randomly divided into atorvastatin group and control group. Atorvastatin group was treated with oral atorvastatin tablets 20 mg· d^- 1 for 20 weeks. The treatments of control group were same to those of atorvastatin group except for oral administration of atorvastatin. RESULTS ： After 20 weeks of treatment, the plasma levels of hs-CRP and IL-18 decreased significantly（P〈0.05 or P〈0.01）, compared with before treatment. And the decrease of atorvastatin group was more evident（P〈0.05）. After 20 weeks of treatment, thickness and plaque size, IMT of carotid artery （IMT） in atorvastatin group was significantly reduced（P〈0.05）, while there was no significant change in quantity of plaque（P〉 0：05）. The size, thickness, quantity and IMT of plaque in control group 0.05）. CONCLUSION： Atorvastatin has anti-inflammatory effect on the can block and reverse coronary atherosclerotic plaques. had no significant difference before and after treatment（P〉 ACS and can improve blood vessel plaque inflammation. It